Sponsor Dossier
Mayne Pharma
Sponsor Dossier for Mayne Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACTIKERALL
- Brand: ASTRIX
- Brand: Budesonide
- Brand: Carbidopa
- Brand: Diltiazem
- Brand: DORYX
- Brand: Eryc
- Brand: FABIOR
- Device (sponsor): Epidermal osmotic dressing, non-sterile
- Device (sponsor): Lice treatment solution, natural
- Device (manufacturer): Irrigation kit, <specify>
- Device (manufacturer): Irrigation fluid, nasal
- Device (manufacturer): Irrigation kit, <specify>
About
Mayne Pharma is an Australian Private Company with ABN 88007870984, registered in South Australia. The entity is active and registered for GST from 1 July 2000.
Portfolio
Mayne Pharma has 22 brands on the ARTG, of which 14 are indexable and 11 carry a Product Information document. 8 brands are PBS-listed, 6 have a PBAC outcome on record, and 3 have an AusPAR on record. Notable brands include ACTIKERALL, ASTRIX, Budesonide, Carbidopa, Diltiazem, DORYX, Eryc, FABIOR, KADIAN, KAPANOL, LOZANOC, Magnoplasm.
Therapeutic focus
— Infectious Disease: 6 brands — Dermatology: 5 brands — Cardiology: 3 brands — Pain Management: 3 brands — Reproductive Health: 2 brands — Neurology: 1 brand — Renal: 1 brand — Gastroenterology: 1 brand
PBS footprint
8 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2025-03-01, across 6 brands with a PBAC outcome on record. The latest AusPAR is 2022-08-11, across 3 brands with an AusPAR on record.